Diligence memo · auto-generated · as of July 2, 2026
Cofactor Genomics, Inc.
Cofactor Genomics, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Cofactor Genomics, Inc. operates in Biotechnology, based in San Francisco, MO, USA. Cofactor closes the precision medicine gap with predictive diagnostics
Sub-sector tags: biotech, healthtech, medical-devices.
Capital & rounds (filed)filed
Cofactor Genomics, Inc. has raised $19M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2017-06-14.
Most recent recorded round closed around 2023-07-20.
Valuation (modeled)modeled
Provath models Cofactor Genomics, Inc. at approximately $9.8M (range $1.3M–$26M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.22× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 37 months.
Last raise 3.0 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 5.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotechnology peers (4293 compared).
Modeled value ranks above 18% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.